phrykt

Kalaris Therapeutics, Inc. (KLRS): who owns it and who trades it

As of Nov 16, 2026, KLRS insiders reported 1 open-market sale worth $12.9K and 2 purchases worth $6.2M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Brett R Hagen (Chief Accounting Officer), with $12.9K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Kalaris Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly bought. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns KLRS

56 funds and institutions reported KLRS shares worth $73.4M at the end of Q2 2026, about 79% of the company. The largest holder is Samsara Biocapital, LLC with 56.2%.

Funds and institutions (13F) 79%Everyone else 21%

10 largest owners, by share of the company

Samsara Biocapital, LLC56.2%
Rtw Investments, LP5.7%
Alyeska Investment Group, L.P.2.5%
Siren, L.L.C.1.9%
Vanguard Capital Management LLC1.7%
Ikarian Capital, LLC1.6%
UBS Group AG1.1%
Renaissance Technologies LLC0.7%
Marshall Wace, LLP0.6%
Geode Capital Management, LLC0.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Samsara Biocapital, LLC12.88M56.18%$52.4M-1%
Rtw Investments, LP1.30M5.67%$5.3MNo change
Alyeska Investment Group, L.P.572,6872.50%$2.3MNo change
Siren, L.L.C.435,7981.90%$1.8MNo change
Vanguard Capital Management LLC398,7121.74%$1.6M+56%
Ikarian Capital, LLC360,0001.57%$1.5MNo change
UBS Group AG262,1311.14%$1.1M+4139%
Renaissance Technologies LLC149,3510.65%$608K+126%
Marshall Wace, LLP139,2010.61%$567K+105%
Geode Capital Management, LLC114,0370.50%$464K+30%
ADAR1 Capital Management, LLC100,0000.44%$407KNo change
Woodline Partners LP100,0000.44%$407KNo change
WHI TRUST Co LLC97,4930.43%$397KNo change
Raymond James Financial Inc97,1640.42%$395K-18%
Citadel Advisors LLC95,7720.42%$390KNew
Boothbay Fund Management, LLC92,2610.40%$376KNo change
Verdad Advisers, LP80,2970.35%$327KNew
Morgan Stanley72,3260.32%$294K+89%
Vanguard Fiduciary Trust Co66,1790.29%$269K+80%
BlackRock, Inc.54,4420.24%$222K+51%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, KLRS insiders reported $6.2M of open-market purchases and $12.9K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$6.2M
2 trades, 2 people
Sales, 12 months
$12.9K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
May 20, 2026
Filed May 22, 2026

Purchases and sales by month

$5M$5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 20, 2026Samsara BioCapital, L.P. +410% ownerPurchase244,300$4.83$1.2MForm 4
Mar 20, 2026Brett R HagenChief Accounting OfficerSale1,915$6.72$12.9KForm 4
Dec 18, 2025Samsara Opportunity Fund, L.P. +410% ownerPurchase479,847$10.42$5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Samsara Opportunity Fund, L.P.10% owner$5M–Dec 18, 2025
Samsara BioCapital, L.P.10% owner$1.2M–May 20, 2026
Brett R HagenChief Accounting Officer–$12.9KMar 20, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

KLRS short interest

Low short interest. 1.5% of KLRS shares are sold short: about 1 share in 65. Over the last 12 reports the number of shares short went down 54%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 366,632 KLRS shares were sold short, 1.5% of the shares outstanding, up 19.7% from the report before. At the average daily volume of 67,573 shares, buying them all back would take about 5.4 trading days (days to cover).

Shares short, % of all shares

1.54%May 15Oct 303.84%

Days to cover

5.4May 15Oct 3013.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026366,6321.54%+20%67,5735.4
Oct 15, 2026306,4001.29%-8%88,6283.5
Sep 30, 2026331,8761.39%+4%72,7714.6
Sep 15, 2026318,3611.34%-8%60,9325.2
Aug 31, 2026345,9901.45%-12%49,0907.0
Aug 14, 2026393,3391.65%-4%63,8636.2
Jul 31, 2026411,6511.80%-21%1.05M1.0
Jul 15, 2026520,1872.27%+4%44,65611.7
Jun 30, 2026502,5782.19%-34%93,5755.4
Jun 15, 2026762,6693.33%-5%69,94710.9
May 29, 2026801,5233.50%-0%77,87910.3
May 15, 2026804,3743.51%-0%101,9257.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Kalaris Therapeutics company events

Kalaris Therapeutics filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Aug 11, 2026ResultsReleased financial results. Filing
  3. Jul 20, 2026LeadershipThe Board of Directors of Kalaris Therapeutics, Inc. appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026. Filing
  4. Jul 17, 2026AnnouncementThe Company issued a press release announcing positive additional data from its Phase 1a SAD clinical trial of TH103 in treatment-naïve patients with nAMD. Data from the expanded cohorts build on previously reported positive findings from the trial, with additional patients showing improvements in… Filing
  5. Jul 6, 2026LeadershipMorana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. of her decision to resign as a member of the Company’s board of directors, effective immediately. Filing
  6. Jun 4, 2026VoteReported shareholder vote results. Filing
  7. May 12, 2026ResultsReleased financial results. Filing
  8. Apr 10, 2026LeadershipMatthew Gall notified Kalaris Therapeutics, Inc. of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026. Filing
  9. Mar 17, 2026ResultsReleased financial results. Filing
  10. Mar 9, 2026AnnouncementShared information with investors. Filing
  11. Dec 18, 2025AgreementKalaris Therapeutics, Inc., a Delaware corporation, entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 4,200,000 shares of the Company’s common… Filing
  12. Dec 17, 2025AnnouncementThe Company issued a press release announcing initial data from its Phase 1a SAD trial of TH103 in treatment-naïve patients with nAMD. The data demonstrate that TH103’s engineered molecular properties translated into clinically meaningful improvements in vision and retinal anatomy, with early… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Kalaris Therapeutics financials

Famous investors that hold KLRS

2 of the 50 well-known investors we track reported holding KLRS in their latest 13F filing. The largest position is Jim Simons's, worth $511K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026176,863$511K0.0%+18%
Ken Griffin · Citadel AdvisorsQ3 202639,219$113K0.0%-59%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KLRS in the last 120 days.

FiledHolderFormStake
Oct 26, 2026Coastlands Capital LP13G5.7%
Oct 26, 2026Coastlands Capital LP13G5.7%

Questions about Kalaris Therapeutics, Inc. (KLRS) stock

Who owns the most KLRS stock?

The largest reported owner of Kalaris Therapeutics, Inc. (KLRS) is Samsara Biocapital, LLC, with 56.2% of the company. In total, 56 funds and institutions reported holding KLRS at the end of Q2 2026, together about 79% of the shares. See the largest owners.

Are KLRS insiders buying or selling?

In the last 12 months, KLRS insiders reported 2 open-market purchases worth $6.2M and 1 sale worth $12.9K. The latest trade was on May 20, 2026. See every trade.

What is the short interest in KLRS?

As of Oct 30, 2026, 366,632 KLRS shares were sold short, 1.5% of the shares outstanding, up 19.7% from the report before. At the average daily volume of 67,573 shares, buying them all back would take about 5.4 trading days (days to cover). See the history.

Which famous investors hold KLRS?

2 of the 50 well-known investors we track reported KLRS in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $511K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.